유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - eitilfrumukrabbamein, mantle-cell - Æxlishemjandi lyf - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - Æxlishemjandi lyf - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - Æxlishemjandi lyf - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

zentiva k.s.* - mometasonum fúróat - nefúði, dreifa - 50 míkróg/skammt

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

alk-abelló a/s - betula verrucosa - stungulyf, dreifa

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

alk-abelló a/s - dermatophagoides pteronyssinus - stungulyf, dreifa

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

alk-abelló a/s - phleum pratense - stungulyf, dreifa